From: Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy
 | All Patients (%) | Patients with ypN0 (%) | Patients with ypN1mi (%) | Patients with ypN+ (%) | P value |
---|---|---|---|---|---|
Total | 978 (100) | 438 (44.8) | 89 (9.1) | 451 (46.1) | Â |
Age at diagnosis, average (range) | 48.5 (20–79) | 48.6 (26–79) | 47.1 (28–75) | 48.8 (20–75) | 0.296 |
Clinical nodal status, initial | Â | Â | Â | Â | 0.061 |
Negative | 51 (5.2) | 31 (7.3) | 3 (3.4) | 17 (3.8) | Â |
Positive | 927 (94.8) | 407 (92.9) | 86 (96.6) | 434 (96.2) | Â |
Breast surgery |  |  |  |  | < 0.001 |
BCS | 369 (37.7) | 198 (45.2) | 40 (44.9) | 131 (29.0) | Â |
Mastectomy | 609 (62.3) | 240 (54.8) | 49 (55.1) | 320 (71.0) | Â |
Pathologic tumor size (mm) |  |  |  |  | < 0.001 |
Breast pCR | 283 (28.9) | 224 (51.1%) | 26 (29.2) | 33 (7.3) | Â |
0–20 | 458 (46.8) | 169 (38.6) | 49 (55.1) | 240 (53.2) |  |
20–50 | 194 (19.8) | 38 (8.7) | 14 (15.7) | 142 (31.5) |  |
>50 | 43 (4.4) | 7 (1.6) | 0 (0) | 36 (8.0) | Â |
Number of dissected LNs, average (range) | 16.7 (10–60) | 16.0 (10–38) | 16.1 (10–31) | 17.4 (10–60) | 0.003 |
ER |  |  |  |  | < 0.001 |
Positive | 572 (58.5) | 186 (42.5) | 60 (67.4) | 326 (72.3) | Â |
Negative | 406 (41.5) | 252 (57.5) | 29 (32.6) | 125 (27.7) | Â |
PR |  |  |  |  | < 0.001 |
Positive | 431 (44.1) | 122 (28.3) | 50 (56.2) | 259 (57.4) | Â |
Negative | 547 (55.9) | 316 (72.1) | 39 (43.8) | 192 (42.6) | Â |
HER2 |  |  |  |  | < 0.001 |
Negative | 638 (65.2) | 237 (54.1) | 63 (70.8) | 338 (74.9) | Â |
Positive | 340 (34.8) | 201 (45.9) | 26 (29.2) | 113 (25.1) | Â |
Ki-67 LI, % |  |  |  |  | < 0.001 |
<14 | 370 (37.8) | 112 (25.6) | 39 (43.8) | 219 (48.6) | Â |
≥14 | 438 (44.8) | 224 (51.1) | 38 (42.7) | 176 (39.0) |  |
Unknown | 170 (17.4) | 102 (23.3) | 12 (13.5) | 56 (12.4) | Â |
Radiotherapy | Â | Â | Â | Â | 0.015 |
Not performed | 78 (8.0) | 47 (10.7) | 4 (4.5) | 27 (6.0) | Â |
Performed | 900 (92.0) | 391 (89.3) | 85 (95.5) | 424 (94.0) | Â |